Michael Gold to Dose-Response Relationship, Drug
This is a "connection" page, showing publications Michael Gold has written about Dose-Response Relationship, Drug.
Connection Strength
0.152
-
A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer. Gynecol Oncol. 2008 Oct; 111(1):89-94.
Score: 0.070
-
A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial. Gynecol Oncol. 2005 Oct; 99(1):50-7.
Score: 0.057
-
ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol. 2004 Feb; 103(2):317-26.
Score: 0.013
-
Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. Am J Obstet Gynecol. 2003 Apr; 188(4):916-26.
Score: 0.012